Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic leukemia cancer (CLL) cells -; their ability to self-renew and resist terminal differentiation and senescence.

To view article click here

Source: Medical.net

Pin It on Pinterest